Primer Capital’s portfolio company, Acticor Biotech announces the signature of an Asset Transfer and Licensing agreement with CMS Medical Limited16 August 2018 Primer Capital’s portfolio company, Acticor Biotech, France – a clinical stage biotechnology company involved in the acute phase of thrombotic diseases, including stroke and pulmonary embolism - announces the signature of an Asset Transfer and Licensing agreement with CMS Medical Limited, a wholly-owned subsidiary of China Medical System Holdings Limited ("CMS").
Acticor Biotech will collaborate with CMS, who has obtained rights to Acticor’s lead candidate in China and other Asian countries (excluding Japan and India) which would enable the development and commercialisation of the company’s pipeline in the region. The parties will coordinate and share data from their respective clinical studies. Acticor Biotech will benefit from CMS investment in the development of the company’s assets in China and will also receive a future commercial milestone payments based on the number of sales made by CMS. It will also receive a royalty from every product marketed by CMS.
Back to the list